Skip to main content

Table 2 Basic characteristics of trials included in the present study

From: Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis

Reference Author Year Metastasis Adjuvant chemotherapy With palliative gastrectomy Without palliative gastrectomy 1-year survival 3-year survival 5-year survival Follow-up(month) HR (95%CI)
Patients number Median survival time (month) Ptaients number Median survival time (month) with PG without PG with PG without PG with PG without PG
1 Kikuchi S [26] 1998 M1 - 63 12.2 59 5.5 NA NA NA NA NA NA 40 0.55 (0.35,0.85)
2 Saidi RF [27] 2006 M0 + M1 ± 24 13.2 81 5.5 NA NA NA NA 5% 0 60 0.46 (0.03,7.2)
3 Nazli O [28] 2007 M0 - 21 8 39 3 NA NA NA NA NA NA 36 NA
4 Lin SZ [29] 2008 M0 + M1 ± 183 NA 206 NA 61.3% 1.3% 8.9% 0 6.2% 0 60 0.61 (0.45,0.82)
5 Lupascu C [30] 2010 M0 + M1 ± 30 17.8 45 6.4 NA NA NA NA NA NA 30 0.78 (0.06,9.64)
6 Zhang JZ [31] 2011 M0 + M1 - 184 16.4 152 5.5 51.4% 0 NA NA NA NA 60 0.64 (0.49,0.84)
7 Sougioultzis S [32] 2011 M0 + M1 + 218 13.25 93 4 NA NA 8.1% 3.5% NA NA 75 0.08 (0.06,0.13)
8 Kim KH [33] 2011 M1 + 47 15.5 185 9 NA NA NA NA NA NA 60 0.65 (0.45,0.94)
9 Chang YR [34] 2011 M1 ± 108 12.7 57 11.2 NA NA NA NA NA NA 60 0.59 (0.42,0.89)
10 Kokkola A [35] 2012 M1 ± 23 10.8 32 5.7 NA NA NA NA NA NA 60 0.99 (0.5,1.94)
11 Chen S [36] 2012 M0 + M1 ± 392 NA 470 NA NA NA NA NA NA NA 48 0.71 (0.58,0.87)
12 Tokunaga M [37] 2012 M1 ± 82 13.1 66 12 NA NA NA NA NA NA 60 1.03 (0.65,1.65)
13 Miki Y [38] 2012 M1 ± 38 25.6 12 8.7 64.4% 36.7% 36.1% 12.2% 29.4% 0 83 0.27 (0.12,0.59)
14 Dittmar Y [39] 2012 M0 + M1 ± 48 15 45 6 NA NA NA NA NA NA 60 0.56 (0.32,0.99)
Total publications: 14     1461 14.96* 1542 7.07*         
  1. +: all patients received chemotherapy. -: chemotherapy was not mentioned. ±: a part of patients received chemotherapy.
  2. *: weighted average of median survival time of articles.